Triptorelin 6-month Formulation Shows Good Efficacy and Safety in Patients with Central Precocious Puberty (CPP)

Presented at PAS 2015 – San Diego

K Klein (1), J Yang (2), J Aisenberg (3), N Wright (4), P Kaplowitz (5), J Linares (6), E Lundström(7), D Purcea (7), F Cassorla(6)

(1)University of California, San Diego, USA;
(2) Arnold Palmer Hospital for Children, Orlando, USA;
(3) Hackensack University Medical Center, Hackensack, USA;
(4)Talahassee, USA;
(5) Children’s National Medical Center, Washington DC, USA;
(6) IDIMI, Santiago de Chile, Chile;
(7) Debiopharm International SA, Lausanne, Switzerland